Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K) vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of calories and energy; sodium chloride and potassium chloride replenish electrolytes and maintain fluid balance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Restoration and maintenance of electrolyte and fluid balance,Treatment of dehydration,Parenteral nutrition supplementation
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion at a rate of 100-200 m L/hour (2-4 m L/kg/hour) based on fluid and electrolyte requirements. Maximum infusion rate: 1000 m L/hour. Adjust according to serum potassium levels.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Not applicable as terminal half-life for dextrose is not defined due to rapid metabolism; for potassium, distribution half-life ~1-1.5 h, terminal half-life ~12-24 h reflecting renal elimination.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized via glycolysis and oxidative phosphorylation; potassium is excreted renally; sodium is excreted renally.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: glucose is completely reabsorbed under normal conditions; excess is excreted unchanged in urine. Sodium, chloride, and potassium are primarily excreted renally, with >90% of infused loads eliminated by kidneys. Fecal and biliary excretion are negligible.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Not determined; glucose and electrolytes are not protein-bound.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Glucose distributes into total body water ~0.55 L/kg; sodium and chloride distribute into extracellular fluid ~0.2 L/kg; potassium distributes into total body water ~0.55 L/kg with preferential intracellular distribution (98% in cells).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR 30-50 m L/min: No dose adjustment; monitor serum potassium. GFR 15-29 m L/min: Reduce potassium to 10-15 m Eq/L or decrease infusion rate by 50%. GFR <15 m L/min: Avoid use; use potassium-free solution or adjust based on serum potassium.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce potassium to 10-15 m Eq/L. Child-Pugh C: Avoid use or use with extreme caution; monitor potassium closely.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Neonates and infants: 0.5-1.0 m Eq/kg/day of potassium; adjust per serum levels. Children: Maintenance fluid with potassium 20-40 m Eq/L at a rate of 100 m L/kg/day for first 10 kg, then 50 m L/kg/day for next 10 kg, then 20 m L/kg/day for additional weight. Maximum infusion rate: 0.5 m Eq/kg/hour.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start at lower infusion rate (50-100 m L/hour) with frequent monitoring of serum potassium and renal function. Avoid if GFR <30 m L/min; use caution in patients with heart failure or hypertension.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None
None.
Risk of fluid overload in patients with cardiac or renal impairment,Hyperkalemia risk with rapid potassium infusion,Phlebitis at infusion site,Monitor serum electrolytes and glucose levels
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia,Severe renal impairment with oliguria,Anuria,Hypersensitivity to any component
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados, tomatoes) and salt substitutes containing potassium chloride. No alcohol restriction is typically required.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
No teratogenic risk; dextrose, sodium chloride, and potassium chloride are physiological substances. No fetal harm reported in any trimester when used as indicated.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Compatible with breastfeeding; components are normal plasma constituents. No M/P ratio available as they are not drugs but nutrients/electrolytes. Excretion in milk mirrors maternal plasma levels.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No dose adjustment required; pharmacokinetics of dextrose, sodium, and potassium are not significantly altered in pregnancy. Adjust only if concurrent conditions like gestational diabetes or preeclampsia.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This combination (D5 0.2% Na Cl with 15 m Eq KCl) is a maintenance fluid for patients with ongoing potassium losses and normal renal function. Monitor serum potassium levels and urine output; avoid in hyperkalemia, renal impairment, or Addison's disease. Infusion rate should not exceed 10-20 m Eq/hour of potassium. Use with caution in patients on potassium-sparing diuretics or ACE inhibitors. Check compatibility with other IV medications.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This fluid contains potassium; do not consume additional potassium supplements or salt substitutes without consulting your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, or tingling sensations immediately.,Tell your healthcare provider if you have kidney problems, heart disease, or are taking certain medications like ACE inhibitors or diuretics.,The infusion rate is carefully controlled; do not adjust the IV drip yourself.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K) vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K) is a Electrolyte that works by Dextrose provides a source of calories and energy; sodium chloride and potassium chloride replenish electrolytes and maintain fluid balance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K) and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K) is: Intravenous infusion at a rate of 100-200 m L/hour (2-4 m L/kg/hour) based on fluid and electrolyte requirements. Maximum infusion rate: 1000 m L/hour. Adjust according to serum potassium levels.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K) and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K) is classified as Category A/B. No teratogenic risk; dextrose, sodium chloride, and potassium chloride are physiological substances. No fetal harm reported in any trimester when used as indicated.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.